Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

International Researchers Call On Rheumatologists To Help Their Patients Stay Fit For Work
Researchers, doctors and patient groups will today call on
generic viagra online
Frankenman International Ltd Secures FDA Clearance For Its Entire CHEX Range Of Surgical Staplers
Frankenman International Ltd, the manufacturer and supplier of surgical instruments, announced that its entire CHEX™ range of surgical staplers had been granted FDA approval. This development complements the CE and ISO accreditation it has already acquired. FDA approval endorses Frankenman"s commitment to total quality in surgical stapling and wound closure devices, and further validates its position as a trusted alternative supplier in these markets.
News of the day
Next Year's Rising Health Costs May Not Be Slowed By Reform
"Employers who offer health insurance coverage could see a 9 percent cost increase next year, and their workers may face an even bigger hit, according to a report Thursday from consulting firm PricewaterhouseCoopers," the Associated Press reports. Workers concerned about losing their jobs" and their insurance, while it lasts - are using more health care than usual, contributing to rising costs, the report says. As the costs increase, employers are also likely to shift more of the burden to employees. "A total of 42% of employers surveyed said they would increase employees" share of costs," the AP reports.
Endocrinology

DxS' TheraScreen(R) K-RAS Companion Diagnostic Approved For Use With Amgen's Vectibix™ In Canada

DxS, a personalised medicine company, has had its TheraScreen: K-RAS Mutation Kit granted a licence by the regulatory body Health Canada for use as a diagnostic for anti-EGFR therapies and as the companion diagnostic for Amgen"s colorectal cancer therapy, Vectibix™ (panitumumab). The availability of the TheraScreen: K-RAS Mutation Kit will allow colorectal cancer patients in Canada to be screened using the DxS diagnostic to assess their suitability for treatment with Vectibix™. Studies have shown that patients with the non-mutated K-RAS gene may respond to treatment with Vectibix™. Approximately 60 per cent of metastatic colorectal cancer patients have a non-mutated K-RAS gene. Colorectal cancer is the third-leading cause of cancer death in Canada, with around 22,000 diagnosed each year, causing 9,100 deaths1. Dr. Kenneth Pritzker, Mount Sinai Services, Toronto, one of the leading centres carrying out K-RAS testing in Canada said "This is extremely good news that we now have a registered method for K-RAS testing. The DxS K-RAS test is simple to use, highly sensitive and is the companion diagnostic test of choice for assessing a patient"s response to Vectibix™." The approval of the TheraScreen: K-RAS Mutation Kit is a step forward in making personalised medicine more readily available to physicians and patients in Canada. The future of cancer treatment will be guided by the use of technological advances such as these, which enable physicians to better manage a patient"s disease or predisposition towards a disease. Now physicians can choose a treatment approach that is likely to work best in the context of a patient"s genetic and environmental profile. Following the global distribution agreement signed in 2008, Roche Diagnostics will be distributing and supporting sales of the TheraScreen: K-RAS Mutation Kit in Canada beginning in August of this year. About colorectal cancer This year an estimated 22,000 Canadians will be diagnosed with colorectal cancer and 9,100 will die from it. On average, 413 Canadians will be diagnosed with colorectal cancer every week and 171 will die from the disease weekly. One in 14 men is expected to develop colorectal cancer during his lifetime and one in 27 will die from it. One in 16 women is expected to develop colorectal cancer during her lifetime and one in 31 will die from it. Overall, colorectal cancer is the third-leading cause of cancer death in Canada. 1 Data from the Colorectal Association of Canada, http://www.colorectal-cancer.ca DxS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009